Key Highlights

• Ansell reported FY26 sales of US$2,140.2 million, up 6.8% year-over-year, with adjusted EPS of US148.6 cents.

• Operating Cash Flow surged 156.3% to US$270.1 million, funding US$118.4 million in share buybacks.

• FY27 adjusted EPS guidance was set at US158 to US170 cents, representing continued Earnings growth.

Shares of Ansell Ltd (ASX:ANN) closed at A$45.52 on 05 November 2026, gaining 4.40% during the session. The S&P/ASX 200 (XJO) advanced 2.61%, adding 230.60 points to close at 9,065.10, while the S&P/ASX 200 Health Care index (XHJ) rose 3.64%, gaining 1,240.30 points to reach 35,329.10. Overnight gains on Wall Street, following Democrats' decisive victory in the U.S. midterm elections, lifted sentiment across global Equity markets. Ansell is a global leader in safety solutions, Manufacturing and distributing protection products across industrial and healthcare markets worldwide.

FY26 Financial Performance

On 24 August 2026, Ansell reported full-year results for the period ended 30 June 2026. Sales reached US$2,140.2 million, an increase of 6.8% on the prior year and 5.0% on an organic constant currency basis. Adjusted EBIT rose 14.1% to US$321.9 million, with the adjusted EBIT Margin expanding 90 basis points to 15.0%. Adjusted net profit after tax grew 15.8% to US$212.3 million, while statutory net profit after tax more than doubled to US$208.6 million. Operating cash flow surged 156.3% to US$270.1 million, with cash conversion reaching 113%.

Segment Breakdown and Tariff Response

The Healthcare segment, which accounted for 56% of segment sales, reported Revenue of US$1,192.9 million, up 8.0% on a reported basis. Growth was led by cleanroom sales, which increased 10.0% on an adjusted basis, driven by Demand from the pharmaceutical and semiconductor industries. The Industrial segment contributed sales of US$947.3 million, up 5.4% on a reported basis, with momentum in mechanical and chemical protection categories. On US tariffs, Ansell noted that sourcing optimisation and price increases offset the effects of higher tariffs. The company applied for and received approximately US$12 million in tariff refunds in July 2026, with the timeline for recovery of the remaining amount described as uncertain.

Capital Management and Dividends

Ansell declared a final unfranked Dividend of US41.5 cents per share, bringing full-year dividends to US68.1 cents per share at a Payout Ratio of 45%. The company's existing US$200 million on-market share buyback programme continued, with US$118.4 million completed in FY26. Net Debt to adjusted EBITDA stood at 1.3x as at 30 June 2026, with total Liquidity of US$752 million in cash and undrawn bank facilities.

About Ansell

Ansell Ltd is a global leader in safety solutions, specialising in the development and manufacture of protection products for industrial and healthcare environments. The company operates across two primary segments — Industrial and Healthcare — and serves customers in sectors including chemical, automotive, aerospace, defence, pharmaceutical and surgical markets. Listed on the ASX, Ansell employs more than 15,000 people globally and has manufacturing operations spanning multiple continents.

Sector Context

The ASX healthcare sector traded higher on 05 November 2026, with the S&P/ASX 200 Health Care index gaining 3.64%. The broader market rally was driven by improved global sentiment following the U.S. midterm election outcome and the associated overnight Wall Street gains. Healthcare equipment and safety product companies benefited from ongoing demand in hospital, laboratory and cleanroom settings, as well as from tariff refund recoveries in the US.

Risks

Key risks include ongoing global macroeconomic uncertainty, which could affect demand across industrial and healthcare end markets. The evolving US tariff landscape and the Middle East crisis continue to impact Supply chains and input costs. Foreign currency movements remain a consideration, as Ansell reports in US dollars but generates revenue across multiple currencies. The Shareholder class action, referenced as a significant item in the results, represents a legal risk.

Catalysts on Watch

Catalysts include continued expansion in cleanroom and scientific verticals, the execution of the new CEO's commercial and operational excellence strategy, progress on ERP system upgrades commencing in North America in FY27, further tariff refund recoveries, and the continuation of the share buyback programme. The FY27 EPS guidance of US158 to US170 cents will serve as a benchmark for the company's earnings trajectory.

The Bottom Line

Ansell's FY26 results reflected revenue and earnings growth across both segments, underpinned by demand in higher-value market segments and disciplined cost management. The FY27 outlook points to continued EPS growth, though the trajectory depends on macroeconomic conditions, tariff outcomes and the successful implementation of the new CEO's strategic priorities. The next update from Ansell is expected at the company's AGM on 9 November 2026.